These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15292711)

  • 1. Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.
    Gullbo J; Lindhagen E; Bashir-Hassan S; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; De La Torre M; Luthman K; Larsson R
    Invest New Drugs; 2004 Nov; 22(4):411-20. PubMed ID: 15292711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan.
    Gullbo J; Dhar S; Luthman K; Ehrsson H; Lewensohn R; Nygren P; Larsson R
    Anticancer Drugs; 2003 Sep; 14(8):617-24. PubMed ID: 14501383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2.
    Gullbo J; Wallinder C; Tullberg M; Lövborg H; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
    Mol Cancer Ther; 2003 Dec; 2(12):1331-9. PubMed ID: 14707274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo.
    Wickström M; Johnsen JI; Ponthan F; Segerström L; Sveinbjörnsson B; Lindskog M; Lövborg H; Viktorsson K; Lewensohn R; Kogner P; Larsson R; Gullbo J
    Mol Cancer Ther; 2007 Sep; 6(9):2409-17. PubMed ID: 17876040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.
    Wickström M; Viktorsson K; Lundholm L; Aesoy R; Nygren H; Sooman L; Fryknäs M; Vogel LK; Lewensohn R; Larsson R; Gullbo J
    Biochem Pharmacol; 2010 May; 79(9):1281-90. PubMed ID: 20067771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1.
    Gullbo J; Wickström M; Tullberg M; Ehrsson H; Lewensohn R; Nygren P; Luthman K; Larsson R
    J Drug Target; 2003 Jul; 11(6):355-63. PubMed ID: 14668056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.
    Gullbo J; Tullberg M; Våbenø J; Ehrsson H; Lewensohn R; Nygren P; Larsson R; Luthman K
    Oncol Res; 2003; 14(3):113-32. PubMed ID: 14760861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.
    Wickström M; Haglund C; Lindman H; Nygren P; Larsson R; Gullbo J
    Invest New Drugs; 2008 Jun; 26(3):195-204. PubMed ID: 17922077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between sensitivity of tumor cells to chemotherapeutic agent in vivo and in vitro: experiment with mouse lymphoma cells].
    Li CG; Li ML; Shu XH; Jia YJ; Liu YJ; Li M
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(22):1576-8. PubMed ID: 17785116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derivatives of melphalan designed to enhance drug accumulation in cancer cells.
    Kupczyk-Subotkowska L; Tamura K; Pal D; Sakaeda T; Siahaan TJ; Stella VJ; Borchardt RT
    J Drug Target; 1997; 4(6):359-70. PubMed ID: 9239576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal Formulation of a Melphalan Lipophilic Prodrug: Studies of Acute Toxicity, Tolerability, and Antitumor Efficacy.
    Tretiakova D; Svirshchevskaya E; Onishchenko N; Alekseeva A; Boldyrev I; Kamyshinsky R; Natykan A; Lokhmotov A; Arantseva D; Shobolov D; Vodovozova E
    Curr Drug Deliv; 2020; 17(4):312-323. PubMed ID: 32056524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
    Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
    Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo activity of melflufen (J1)in lymphoma.
    Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J
    BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel transport and delivery mechanism underpins the effectiveness of prolyl-m-sarcolysyl-p-fluorophenylalanine (PSF) in a human melanoma xenograft nude-mouse model.
    Dierickx KM; Morandini R; Nguyen TH; Salès F; Kauffmann JM; Ghanem GE
    Pigment Cell Melanoma Res; 2008 Aug; 21(4):439-50. PubMed ID: 18627526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mouse model of isolated limb perfusion for extremity melanoma.
    Kim M; Camoriano M; Muhitch JB; Kane JM; Skitzki JJ
    J Surg Res; 2012 Nov; 178(1):294-8. PubMed ID: 22494912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High anticancer efficacy of L-proline-m-bis (2-chloroethyl) amino-L-phenylalanyl-L-norvaline ethyl ester hydrochloride (MF13) in vivo.
    Jiang JD; Zhang H; Li JN; Roboz J; Qiao WB; Holland JF; Bekesi G
    Anticancer Res; 2001; 21(3B):1681-9. PubMed ID: 11497247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Changes and significance of peripheral blood count in tumor rejection induced by a low dose of melphalan in C57BL/6 mice].
    Shu XH; Li CG; Li ML; Michael N; Qin ZH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Jun; 25(6):498-500. PubMed ID: 19500501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of beta-alanyl-melphalan as a potent anticancer drug.
    Tsay BL; Wolfinbarger L
    Cancer Chemother Pharmacol; 1987; 19(3):190-6. PubMed ID: 3581413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
    Alley MC; Hollingshead MG; Pacula-Cox CM; Waud WR; Hartley JA; Howard PW; Gregson SJ; Thurston DE; Sausville EA
    Cancer Res; 2004 Sep; 64(18):6700-6. PubMed ID: 15374987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
    Caffrey PB; Zhang Y; Frenkel GD
    Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.